Analyst Andrew Berens of Leerink Partners maintained a Buy rating on Merus (MRUS – Research Report), with a price target of $88.00.
Andrew Berens has given his Buy rating due to a combination of factors including Merus’s promising pipeline developments and financial stability. The company has narrowed its guidance for the Phase 2 data update in first-line head and neck squamous cell carcinoma (HNSCC) patients to the first half of 2025, with the potential for significant data presentation at ASCO 2025. This update is particularly noteworthy as a majority of responders remain on treatment, indicating promising durability and overall survival outcomes.
Additionally, Merus is progressing with its Phase 3 registrational trials for both first-line PD-L1+ HNSCC patients and second/third-line recurrent/metastatic HNSCC patients, with substantial enrollment expected by the end of 2025. The company is also advancing its colorectal cancer (CRC) trials, with a clinical update anticipated in the second half of 2025. Furthermore, Merus’s ongoing trials in non-small cell lung cancer (NSCLC) and its solid cash position, which is expected to sustain operations into 2028, further support the positive outlook and Buy rating.
Berens covers the Healthcare sector, focusing on stocks such as AstraZeneca, Incyte, and Agios Pharma. According to TipRanks, Berens has an average return of -7.4% and a 35.67% success rate on recommended stocks.
Questions or Comments about the article? Write to editor@tipranks.com